Immunological Barriers to Stem-Cell Based Cardiac Repair

Stem Cell Reviews and Reports

Volumn 7, Issue 2, 2011, Pages 315-325

  Karabekian, Zaruhi ^a   Posnack, Nikki Gillum ^a   Sarvazyan, Narine ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Cardiomyocytes; Differentiation; Embryonic stem cells; Immunogenicity; Induced pluripotent stem cells

Indexed keywords

DIFFERENTIATION ANTIGEN;

ANIMAL; CELL DIFFERENTIATION; CULTURE TECHNIQUE; CYTOLOGY; EMBRYONIC STEM CELL; GRAFT REJECTION; HEART DISEASE; HEART MUSCLE; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; PLURIPOTENT STEM CELL; REGENERATION; REVIEW; TRANSPLANTATION;

ANIMALS; ANTIGENS, DIFFERENTIATION; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; EMBRYONIC STEM CELLS; GRAFT REJECTION; HEART DISEASES; HUMANS; MYOCARDIUM; PLURIPOTENT STEM CELLS; REGENERATION;

EID: 79954996496     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-010-9202-x     Document Type: Review

References (108)

1. Zak, R. (1974). Development and proliferative capacity of cardiac muscle cells. Circulation Research, 35(suppl II), 17-26.
2. Bergmann, O., Bhardwaj, R. D., Bernard, S., et al. (2009). Evidence for cardiomyocyte renewal in humans. Science, 324, 98-102.
3. Pasumarthi, K. B., & Field, L. J. (2002). Cardiomyocyte cell cycle regulation. Circulation Research, 90, 1044-1054.
4. Hodgson, D. M., Behfar, A., Zingman, L. V., et al. (2004). Stable benefit of embryonic stem cell therapy in myocardial infarction. American Journal of Physiology. Heart and Circulatory Physiology, 287, H471-H479.
5. Caspi, O., Huber, I., Kehat, I., et al. (2007). Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts. Journal of the American College of Cardiology, 50, 1884-1893.
6. Tomescot, A., Leschik, J., Bellamy, V., et al. (2007). Differentiation in vivo of cardiac committed human embryonic stem cells in postmyocardial infarcted rats. Stem Cells, 25, 2200-2205.
7. Singla, D. K., Hacker, T. A., Ma, L., et al. (2006). Transplantation of embryonic stem cells into the infarcted mouse heart: formation of multiple cell types. Journal of Molecular and Cellular Cardiology, 40, 195-200.
8. Blank, A. C., van Veen, T. A., Jonsson, M. K., et al. (2009). Rewiring the heart: stem cell therapy to restore normal cardiac excitability and conduction. Current Stem Cell Research & Therapy, 4, 23-33.
9. Rosen, M. R., Brink, P. R., Cohen, I. S., & Robinson, R. B. (2004). Genes, stem cells and biological pacemakers. Cardiovascular Research, 64, 12-23.
10. Laflamme, M. A., Zbinden, S., Epstein, S. E., & Murry, C. E. (2007). Cell-based therapy for myocardial ischemia and infarction: pathophysiological mechanisms. Annual Review of Pathology, 2, 307-339.
11. Stevens, K. R., Kreutziger, K. L., Dupras, S. K., et al. (2009). Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proceedings of the National Academy of Sciences of the United States of America, 106, 16568-16573.
12. Hosoda, T., D'Amario, D., Cabral-Da-Silva, M. C., et al. (2009). Clonality of mouse and human cardiomyogenesis in vivo. Proceedings of the National Academy of Sciences of the United States of America, 106, 17169-17174.
13. Hwang, W. S., Ryu, Y. J., Park, J. H., et al. (2004). Evidence of a pluripotent human embryonic stem cell line derived from a cloned blastocyst. Science, 303, 1669-1674.
14. Davis, D. R., Ruckdeschel Smith, R., & Marban, E. (2010). Human cardiospheres are a source of stem cells with cardiomyogenic potential. Stem Cells, 28, 903-904.
15. Nishiyama, N., Miyoshi, S., Hida, N., et al. (2007). The significant cardiomyogenic potential of human umbilical cord blood-derived mesenchymal stem cells in vitro. Stem Cells, 25, 2017-2024.
16. Yu, J., Vodyanik, M. A., Smuga-Otto, K., et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science, 318, 1917-1920.
17. Takahashi, K., Tanabe, K., Ohnuki, M., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131, 861-872.
18. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126, 663-676.
19. Barile, L., Messina, E., Giacomello, A., & Marban, E. (2007). Endogenous cardiac stem cells. Progress in Cardiovascular Diseases, 50, 31-48.
20. Bearzi, C., Rota, M., Hosoda, T., et al. (2007). Human cardiac stem cells. Proceedings of the National Academy of Sciences of the United States of America, 104, 14068-14073.
21. Linke, A., Muller, P., Nurzynska, D., et al. (2005). Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proceedings of the National Academy of Sciences of the United States of America, 102, 8966-8971.
22. Martin, G. R. (1981). Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proceedings of the National Academy of Sciences of the United States of America, 78, 7634-7638.
23. Evans, M. J., & Kaufman, M. H. (1981). Establishment in culture of pluripotential cells from mouse embryos. Nature, 292, 154-156.
24. Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., et al. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282, 1145-1147.
25. Reubinoff, B. E., Pera, M. F., Fong, C. Y., Trounson, A., & Bongso, A. (2000). Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nature Biotechnology, 18, 399-404.
26. Winkel, G. K., & Pedersen, R. A. (1988). Fate of the inner cell mass in mouse embryos as studied by microinjection of lineage tracers. Developmental Biology, 127, 143-156.
27. Odorico, J. S., Kaufman, D. S., & Thomson, J. A. (2001). Multilineage differentiation from human embryonic stem cell lines. Stem Cells, 19, 193-204.
28. Zhang, J., Wilson, G. F., Soerens, A. G., et al. (2009). Functional cardiomyocytes derived from human induced pluripotent stem cells. Circulation Research, 104, e30-e41.
29. Woltjen, K., Michael, I. P., Mohseni, P., et al. (2009). piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature, 458, 766-770.
30. Kaji, K., Norrby, K., Paca, A., Mileikovsky, M., Mohseni, P., & Woltjen, K. (2009). Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature, 458, 771-775.
31. Warren, L., Manos, P. D., Ahfeldt, T., et al. (2010). Highly Efficient Reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell, 7, 1-13.
32. Wobus, A. M., Wallukat, G., & Hescheler, J. (1991). Pluripotent mouse embryonic stem cells are able to differentiate into cardiomyocytes expressing chronotropic responses to adrenergic and cholinergic agents and Ca2+ channel blockers. Differentiation, 48, 173-182.
33. Gepstein, L. (2002). Derivation and potential applications of human embryonic stem cells. Circulation Research, 91, 866-876.
34. Kehat, I., Kenyagin-Karsenti, D., Snir, M., et al. (2001). Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. Journal of Clinical Investigation, 108, 407-414.
35. Doetschman, T. C., Eistetter, H., Katz, M., Schmidt, W., & Kemler, R. (1985). The in vitro development of blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium. Journal of Embryology and Experimental Morphology, 87, 27-45.
36. Boheler, K. R., Czyz, J., Tweedie, D., Yang, H. T., Anisimov, S. V., & Wobus, A. M. (2002). Differentiation of pluripotent embryonic stem cells into cardiomyocytes. Circulation Research, 91, 189-201.
37. Wobus, A. M., & Guan, K. (1998). Embryonic stem cell-derived cardiac differentiation: modulation of differentiation and "loss-of-function" analysis in vitro. Trends in Cardiovascular Medicine, 8, 64-74.
38. Karabekian, Z., Gillum, N. D., Wong, E. W., & Sarvazyan, N. (2009). Effects of N-cadherin overexpression on the adhesion properties of embryonic stem cells. Cell Adhesion & Migration, 3, 305-310.
39. Laflamme, M. A., Chen, K. Y., Naumova, A. V., et al. (2007). Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nature Biotechnology, 25, 1015-1024.
40. Takahashi, T., Lord, B., Schulze, P. C., et al. (2003). Ascorbic acid enhances differentiation of embryonic stem cells into cardiac myocytes. Circulation, 107, 1912-1916.
41. Wobus, A. M., Kaomei, G., Shan, J., et al. (1997). Retinoic acid accelerates embryonic stem cell-derived cardiac differentiation and enhances development of ventricular cardiomyocytes. Journal of Molecular and Cellular Cardiology, 29, 1525-1539.
42. Behfar, A., Perez-Terzic, C., Faustino, R. S., et al. (2007). Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. The Journal of Experimental Medicine, 204, 405-420.
43. Cerdan, C., Hong, S. H., & Bhatia, M. (2007). Formation and hematopoietic differentiation of human embryoid bodies by suspension and hanging drop cultures. Current Protocols in Stem Cell Biology Chapter 1: Unit 1D. 2.
44. Murry, C. E., Reinecke, H., & Pabon, L. M. (2006). Regeneration gaps: observations on stem cells and cardiac repair. Journal of the American College of Cardiology, 47, 1777-1785.
45. Klug, M. G., Soonpaa, M. H., Koh, G. Y., & Field, L. J. (1996). Genetically selected cardiomyocytes from differentiating embronic stem cells form stable intracardiac grafts. Journal of Clinical Investigation, 98, 216-224.
46. Zandstra, P. W., Bauwens, C., Yin, T., et al. (2003). Scalable production of embryonic stem cell-derived cardiomyocytes. Tissue Engineering, 9, 767-778.
47. Kita-Matsuo, H., Barcova, M., Prigozhina, N., et al. (2009). Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes. PLoS ONE, 4, e5046.
48. Anderson, D., Self, T., Mellor, I. R., Goh, G., Hill, S. J., & Denning, C. (2007). Transgenic enrichment of cardiomyocytes from human embryonic stem cells. Molecular Therapy, 15, 2027-2036.
49. Kolossov, E., Bostani, T., Roell, W., et al. (2006). Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium. The Journal of Experimental Medicine, 203, 2315-2327.
50. Hattori, F., Chen, H., Yamashita, H., et al. (2010). Nongenetic method for purifying stem cell-derived cardiomyocytes. Nature Methods, 7, 61-66.
51. Lui, K. O., Waldmann, H., & Fairchild, P. J. (2009). Embryonic stem cells: overcoming the immunological barriers to cell replacement therapy. Current Stem Cell Research & Therapy, 4, 70-80.
52. He, Q., Trindade, P. T., Stumm, M., et al. (2009). Fate of undifferentiated mouse embryonic stem cells within the rat heart: role of myocardial infarction and immune suppression. Journal of Cellular and Molecular Medicine, 13, 188-201.
53. Molne, J., Bjorquist, P., Andersson, K., et al. (2008). Blood group ABO antigen expression in human embryonic stem cells and in differentiated hepatocyte- and cardiomyocyte-like cells. Transplantation, 86, 1407-1413.
54. Chan, J. H., Dua, H. S., Powell-Richards, A., Jones, D. R., & Harris, I. M. (2001). Effect of ABO blood group mismatching on corneal epithelial cells: an in vitro study. The British Journal of Ophthalmology, 85, 1104-1109.
55. Simpson, E., Roopenian, D., & Goulmy, E. (1998). Much ado about minor histocompatibility antigens. Immunology Today, 19, 108-112.
56. Spierings, E., & Goulmy, E. (2005). Expanding the immunotherapeutic potential of minor histocompatibility antigens. Journal of Clinical Investigation, 115, 3397-3400.
57. Dierselhuis, M., & Goulmy, E. (2009). The relevance of minor histocompatibility antigens in solid organ transplantation. Current Opinion in Organ Transplantation, 14, 419-425.
58. Spierings, E., Hendriks, M., Absi, L., et al. (2007). Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations. PLoS Genetics, 3, e103.
59. Fairchild, P. J., Robertson, N. J., Minger, S. L., & Waldmann, H. (2007). Embryonic stem cells: protecting pluripotency from alloreactivity. Current Opinion in Immunology, 19, 596-602.
60. Boyd, A. S., & Wood, K. J. (2009). Variation in MHC expression between undifferentiated mouse ES cells and ES cell-derived insulin-producing cell clusters. Transplantation, 87, 1300-1304.
61. Drukker, M., Katchman, H., Katz, G., et al. (2006). Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells, 24, 221-229.
62. Suarez-Alvarez, B., Rodriguez, R. M., Calvanese, V., et al. (2010). Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells. PLoS ONE, 5, e10192.
63. Ardehali, A., Laks, H., Drinkwater, D. C., Jr, et al. (1993). Expression of major histocompatibility antigens and vascular adhesion molecules on human cardiac allografts preserved in University of Wisconsin solution. Journal of Heart and Lung Transplantation, 12: 1044, 51; 1051-1052.
64. Choi, J. H., Do, Y., Cheong, C., et al. (2009). Identification of antigen-presenting dendritic cells in mouse aorta and cardiac valves. The Journal of Experimental Medicine, 206, 497-505.
65. Zimmermann, W. H., Melnychenko, I., Wasmeier, G., et al. (2006). Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Natural Medicines, 12, 452-458.
66. Maidhof, R., Marsano, A., Lee, E. J., & Vunjak-Novakovic, G. (2010). Perfusion seeding of channeled elastomeric scaffolds with myocytes and endothelial cells for cardiac tissue engineering. Biotechnology Progress, 26, 565-572.
67. Yoshida, T., Hanawa, H., Toba, K., et al. (2005). Expression of immunological molecules by cardiomyocytes and inflammatory and interstitial cells in rat autoimmune myocarditis. Cardiovascular Research, 68, 278-288.
68. Frantz, S., Bauersachs, J., & Ertl, G. (2009). Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovascular Research, 81, 474-481.
69. Ladhoff, J., Bader, M., Brosel, S., et al. (2009). Low immunogenicity of endothelial derivatives from rat embryonic stem cell-like cells. Cell Research, 19, 507-518.
70. Grinnemo, K. H., Kumagai-Braesch, M., Mansson-Broberg, A., et al. (2006). Human embryonic stem cells are immunogenic in allogeneic and xenogeneic settings. Reproductive Biomedicine Online, 13, 712-724.
71. Drukker, M., Katz, G., Urbach, A., et al. (2002). Characterization of the expression of MHC proteins in human embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America, 99, 9864-9869.
72. Li, L., Baroja, M. L., Majumdar, A., et al. (2004). Human embryonic stem cells possess immune-privileged properties. Stem Cells, 22, 448-456.
73. Koch, C. A., Geraldes, P., & Platt, J. L. (2008). Immunosuppression by embryonic stem cells. Stem Cells, 26, 89-98.
74. Bonde, S., & Zavazava, N. (2006). Immunogenicity and engraftment of mouse embryonic stem cells in allogeneic recipients. Stem Cells, 24, 2192-2201.
75. Swijnenburg, R. J., Schrepfer, S., Cao, F., et al. (2008). In vivo imaging of embryonic stem cells reveals patterns of survival and immune rejection following transplantation. Stem Cells and Development, 17, 1023-1029.
76. Kofidis, T., deBruin, J. L., Tanaka, M., et al. (2005). They are not stealthy in the heart: embryonic stem cells trigger cell infiltration, humoral and T-lymphocyte-based host immune response. European Journal of Cardiothoracic Surgery, 28, 461-466.
77. Nussbaum, J., Minami, E., Laflamme, M. A., et al. (2007). Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. The FASEB Journal, 21, 1345-1357.
78. Raulet, D. H. (2006). Missing self recognition and self tolerance of natural killer (NK) cells. Seminars in Immunology, 18, 145-150.
79. Manilay, J. O., & Sykes, M. (1998). Natural killer cells and their role in graft rejection. Current Opinion in Immunology, 10, 532-538.
80. Joncker, N. T., & Raulet, D. H. (2008). Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells. Immunological Reviews, 224, 85-97.
81. Frenzel, L. P., Abdullah, Z., Kriegeskorte, A. K., et al. (2009). Role of natural-killer group 2 member D ligands and intercellular adhesion molecule 1 in natural killer cell-mediated lysis of murine embryonic stem cells and embryonic stem cell-derived cardiomyocytes. Stem Cells, 27, 307-316.
82. Dressel, R., Nolte, J., Elsner, L., et al. (2010). Pluripotent stem cells are highly susceptible targets for syngeneic, allogeneic, and xenogeneic natural killer cells. The FASEB Journal, 24, 2164-2177.
83. Dressel, R., Schindehütte, J., Kuhlmann, T., et al. (2008). The tumorigenicity of mouse embryonic stem cells and in vitro differentiated neuronal cells is controlled by the recipients' immune response. PLoS ONE, 3, e2622.
84. Steller, H. (1995). Mechanisms and genes of cellular suicide. Science, 267, 1445-1449.
85. Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., & Ferguson, T. A. (1995). Fas ligand-induced apoptosis as a mechanism of immune privilege. Science, 270, 1189-1192.
86. Fandrich, F., Lin, X., Chai, G. X., et al. (2002). Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning. Natural Medicines, 8, 171-178.
87. Mazar, J., Thomas, M., Bezrukov, L., et al. (2009). Cytotoxicity mediated by the Fas ligand (FasL)-activated apoptotic pathway in stem cells. The Journal of Biological Chemistry, 284, 22022-22028.
88. Bachmann, M. F., Speiser, D. E., Mak, T. W., & Ohashi, P. S. (1999). Absence of co-stimulation and not the intensity of TCR signaling is critical for the induction of T cell unresponsiveness in vivo. European Journal of Immunology, 29, 2156-2166.
89. Boggs, J. M., Chang, N. H., Goundalkar, A., & Hashim, G. A. (1992). Stimulation or tolerization of an anti-myelin basic protein T lymphocyte line with membrane fragments from antigen presenting cells. Cellular Immunology, 143, 23-40.
90. Robertson, N. J., Brook, F. A., Gardner, R. L., Cobbold, S. P., Waldmann, H., & Fairchild, P. J. (2007). Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance. Proceedings of the National Academy of Sciences of the United States of America, 104, 20920-20925.
91. Ling, V., Munroe, R. C., Murphy, E. A., & Gray, G. S. (1998). Embryonic stem cells and embryoid bodies express lymphocyte costimulatory molecules. Experimental Cell Research, 241, 55-65.
92. Imitola, J., Comabella, M., Chandraker, A. K., et al. (2004). Neural stem/progenitor cells express costimulatory molecules that are differentially regulated by inflammatory and apoptotic stimuli. The American Journal of Pathology, 164, 1615-1625.
93. Gutierrez-Aranda, I., Ramos-Mejia, V., Bueno, C., et al. (2010). Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection. Stem Cells, 28, 1568-1570.
94. Swijnenburg, R. J., Tanaka, M., Vogel, H., et al. (2005). Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation, 112, I166-I172.
95. Dressel, R., Guan, K., Nolte, J., et al. (2009). Multipotent adult germ-line stem cells, like other pluripotent stem cells, can be killed by cytotoxic T lymphocytes despite low expression of major histocompatibility complex class I molecules. Biology Direct, 4, 31.
96. Bikoff, E. K., Jaffe, L., Ribaudo, R. K., Otten, G. R., Germain, R. N., & Robertson, E. J. (1991). MHC class I surface expression in embryo-derived cell lines inducible with peptide or interferon. Nature, 354, 235-238.
97. Plebanski, M., Katsara, M., Sheng, K. C., Xiang, S. D., & Apostolopoulos, V. (2010). Methods to measure T-cell responses. Expert Reviews of Vaccines, 9, 595-600.
98. Grinnemo, K. H., Sylven, C., Hovatta, O., Dellgren, G., & Corbascio, M. (2008). Immunogenicity of human embryonic stem cells. Cell and Tissue Research, 331, 67-78.
99. Green, D. R., & Ferguson, T. A. (2001). The role of Fas ligand in immune privilege. Nature Reviews. Molecular Cell Biology, 2, 917-924.
100. Abdullah, Z., Saric, T., Kashkar, H., et al. (2007). Serpin-6 expression protects embryonic stem cells from lysis by antigen-specific CTL. Journal of Immunology, 178, 3390-3399.
101. Zijlstra, M., Bix, M., Simister, N. E., Loring, J. M., Raulet, D. H., & Jaenisch, R. (1990). Beta 2-microglobulin deficient mice lack CD4-8+ cytolytic T cells. Nature, 344, 742-746.
102. Haga, K., Lemp, N. A., Logg, C. R., et al. (2006). Permanent, lowered HLA class I expression using lentivirus vectors with shRNA constructs: averting cytotoxicity by alloreactive T lymphocytes. Transplantation Proceedings, 38, 3184-3188.
103. Figueiredo, C., Horn, P. A., Blasczyk, R., & Seltsam, A. (2007). Regulating MHC expression for cellular therapeutics. Transfusion, 47, 18-27.
104. Figueiredo, C., Seltsam, A., & Blasczyk, R. (2006). Class-, gene-, and group-specific HLA silencing by lentiviral shRNA delivery. Journal of Molecular Medicine, 84, 425-437.
105. Horn, P. A., Figueiredo, C., & Kiem, H. P. (2007). Gene therapy in the transplantation of allogeneic organs and stem cells. Current Gene Therapy, 7, 458-468.
106. Figueiredo, C., Goudeva, L., Horn, P. A., Eiz-Vesper, B., Blasczyk, R., & Seltsam, A. (2010). Generation of HLA-deficient platelets from hematopoietic progenitor cells. Transfusion, 50, 1690-1701.
107. Grusby, M. J., Auchincloss, H., Jr., Lee, R., et al. (1993). Mice lacking major histocompatibility complex class I and class II molecules. Proceedings of the National Academy of Sciences of the United States of America, 90, 3913-3917.
108. Dierich, A., Chan, S. H., Benoist, C., & Mathis, D. (1993). Graft rejection by T cells not restricted by conventional major histocompatibility complex molecules. European Journal of Immunology, 23, 2725-2728.